NASDAQ$ITOS
iTeos Therapeutics Inc · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
iTeos Therapeutics reported Q2 2025 a net loss of $78.7M.
For Q2 2025, iTeos Therapeutics reported net loss was $78.7M. Management discusses segment trends, liquidity, and outlook in the quarterly filing.
- Net loss $78.7M.
- MD&A highlights operating priorities, liquidity, and sector risks.
- MD&A highlights operating priorities, liquidity, and sector risks.
Headline financials
Revenue & EPS history
iTeos Therapeutics · Revenue · Quarterly
$35M
Forward guidance
Biopharma outlook emphasizes pipeline milestones, launch uptake, and R&D spend.
Tailwinds
- Clinical data and partnership economics.
- Cash runway supports key readouts.
Headwinds
- Trial risk and regulatory timelines.
- Competition and reimbursement pressure.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 6 quarterly earnings reports · overlaid with Q2 2025
+0.8%
Avg return
Earnings day
+7.3%
Avg return
5 days after
+11.8%
Avg return
30 days after
38%
8 / 21 earnings
Positive
+39.6%
Q1 2024
Best reaction
-11.1%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | — | — | — | |
| Q2 2025 | +0.2% | +0.0% | — | |
| Q1 2025 | -0.4% | +13.3% | +52.2% | |
| Q4 2024 | -3.7% | -6.4% | -11.4% | |
| Q3 2024 | -5.9% | -12.4% | -15.6% | |
| Q2 2024 | -3.4% | +1.4% | -3.1% | |
| Q1 2024 | +39.6% | +47.5% | +36.9% | |
| Q4 2023 | +5.1% | +8.0% | +12.0% | |
| Q3 2023 | -3.1% | — | — | |
| Q2 2023 | -2.6% | — | — | |
| Q1 2023 | -0.8% | — | — | |
| Q4 2022 | -7.7% | — | — | |
| Q3 2022 | +16.2% | — | — | |
| Q2 2022 | -9.4% | — | — | |
| Q1 2022 | +3.2% | — | — | |
| Q4 2021 | -3.6% | — | — | |
| Q3 2021 | +1.4% | — | — | |
| Q2 2021 | -1.5% | — | — | |
| Q1 2021 | +8.5% | — | — | |
| Q4 2020 | -11.1% | — | — | |
| Q3 2020 | -4.2% | — | — | |
| Q2 2020 | +0.0% | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro